Long-term safety and benefits of SHR-1703 for adults with eosinophilic asthma

A Multicenter, Single-group Phase II Clinical Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of Multiple Subcutaneous Injections of SHR-1703 in Eosinophilic Asthma Patients

This research will test whether regular SHR-1703 injections are safe over the long term and help control symptoms in adults with eosinophilic asthma who remain symptomatic despite medium- to high-dose inhaled steroids.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd (Industry-sponsored)
• Drugs / interventions: methotrexate
• Locations: 1 site (Chengdu, Sichuan)
• Trial ID: NCT06441812 on ClinicalTrials.gov

What this trial studies

This Phase 2 interventional study gives adults with eosinophilic asthma repeated SHR-1703 injections and follows them over an extended period to collect safety, pharmacodynamic, and efficacy data. Eligible participants must have documented asthma for at least one year, blood eosinophil counts ≥0.15×10^9/L, a pre-bronchodilator FEV1 between 30% and 85% predicted, and recent exacerbation history while on medium/high-dose inhaled corticosteroids plus at least one additional controller. Study outcomes will include adverse events, changes in eosinophil counts, lung function (FEV1), and exacerbation frequency. The protocol requires on-site visits at the listed clinical center for dosing and monitoring.

Who should consider this trial

Good fit: Adults (≥18 years) with eosinophilic asthma, blood eosinophils ≥0.15×10^9/L, pre-bronchodilator FEV1 30–85% predicted, history of at least one exacerbation in the prior year, and on stable medium or high-dose inhaled corticosteroid plus another controller are the intended participants.

Not a fit: People with non-eosinophilic asthma, well-controlled disease on low-dose inhaled steroids, or significant contraindicating comorbidities are less likely to benefit from this treatment.

Why it matters

Potential benefit: If successful, SHR-1703 could reduce exacerbations and improve lung function and symptom control for adults with eosinophilic asthma not controlled on current controller therapy.

How similar studies have performed: Other biologic treatments targeting eosinophilic pathways (for example, anti–IL-5/IL-5R agents) have shown clinical benefit, so the class approach has precedent though SHR-1703 itself remains under study.

Eligibility criteria

Inclusion Criteria:

1. At least 18 years of age, Male or Femal.
2. A minimum weight of 40kg.
3. Subjects with the clinical features of asthma that meets the diagnostic criteria of the "Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 Edition)" and has a medical history of at least 1 year.
4. Documentation of current asthma controller medication \[medium or high dose ICS and at least one of additional controller such as long-acting muscarinic antagonist (LAMA), long-acting beta2-agonist (LABA) and leukotriene receptor antagonist (LTRA)\] for at least 1 stable month before first administration of SHR-1703.
5. At least one confirmed history of exacerbation within one year of initial administration of SHR-1703, occurring during the use of medium and high daily dose ICS.
6. Absolute count of eosinophils must be ≥0.15×109/L at visit 0 and visit 1.
7. A pre-bronchodilator FEV1 \<85% and ≥30% predicted at visit 0 and visit 1.
8. Female subjects with fertility agree to have no plan pregnancy and voluntarily adopt high-efficiency contraception measures from signing the informed consent form to 14 months after the last dose of SHR-1703, and male subjects with fertility as partners agree to have no plan pregnancy and voluntarily adopt high-efficiency contraception measures between the first dose of SHR-1703 and the last visit in the study.
9. Subjects must be able to give written informed consent prior to participation in the study.

Exclusion Criteria:

1. Presence of a clinically important lung condition. This includes but is not limited to current infection, bronchiectasis, pulmonary fibrosis or a history of lung cancer.
2. A known immunodeficiency.
3. Presence of a clinically significant and uncontrolled serious cardiovascular and cerebrovascular disease, including but not limited to myocardial infarction, unstable angina, heart failure, stroke, and subarachnoid haemorrhage.
4. Within the first 4 weeks before visit 0, presence of exacerbation of allergic rhinitis or sinusitis, or a history of infections with clinical significance and/or requiring clinical intervention, including but not limited to respiratory infections.
5. A known parasitic infection within the first 6 months before visit 0.
6. A malignancy history within the first 5 years before visit 0 (Subjects that had localized basal carcinoma of the skin or cervical carcinoma in situ which was resected for cure will not be excluded).
7. Blood donation or significant blood loss (≥ 400ml) within the first 4 weeks before visit 0, or infusion of blood products or immunoglobulins.
8. Use systemic immunosuppressants (excluding systemic glucocorticoids used for asthma treatment and for non asthma treatment for less than 3 days) or immunomodulators, or biologics or Th2 cytokine inhibitors, including but not limited to methotrexate, cyclosporine, interferon-α, anti IL-5 monoclonal antibodies (including SHR-1703), anti IL-4R monoclonal antibodies, anti TSLP monoclonal antibodies, anti IgE monoclonal antibodies, metformin, etc., and within 5 half-lives of the drug before the first administration (refer to the longer drug instructions; for those with unknown half-lives, 12 weeks before the first administration shall prevail);
9. Subjects who have previously participated in any study and received Investigational Product within the first 30 days before visit 0.
10. There was a surgical plan or other treatment measures that the researcher believed may affect the subject's evaluation during the study period.
11. Laboratory examination shows obvious abnormalities at visit 0 and visit 1:

    1. White blood cell count (WBC) \<3.0×109/L;
    2. Hemoglobin≤90g/L；
    3. Platelet\<100×109/L；
    4. Alanine aminotransferase (ALT)\>2×ULN (upper limit of normal);
    5. Aspartate aminotransferase (AST) \>2×ULN；
    6. Total bilirubin (TBIL)\>1.5×ULN;
    7. Prothrombin time (PT) \>ULN+3s；
    8. Creatinin\>1.5×ULN;
    9. Active hepatitis B (positive for hepatitis B virus deoxyribonucleic acid (HBV DNA) in peripheral blood), or positive for hepatitis C virus antibody, or positive for human immunodeficiency virus (HIV) antibody, or positive for treponema pallidum antibody；
12. ECG QTc\>450ms or other clinically significant abnormal results that may pose significant safety risks to the subjects at visit 0 or visit 1；
13. A history of drug addicts or substance abuse within 1 years prior to Visit 0；
14. Subjects who are pregnant (positive HCG test at visit 0 or visit 1) or breastfeeding should not be enrolled if they plan to become pregnant during the time of study participation；
15. Subjects with a known allergy or intolerance to anti IL-5 monoclonal antibody or other biologic；
16. Other reasons determined by the researcher as unsuitable for participation in the study.

Where this trial is running

Chengdu, Sichuan

• West China Hospital of Sichuan University — Chengdu, Sichuan, China (Recruiting)

Study contacts

• Study coordinator: Tianqi Zheng

Conditions Eosinophilic Asthma Patients